Yearly Archives: 2026
Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)
New PATHOMIQ AI integration helps clinicians tailor active surveillance with greater confidence
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
Joint development strategy has been developed to address international deployment requirements if current outbreak continues or expands globally
NanoKar Therapeutics Announces Formal Appointment of Craig Mosman as Chief Executive Officer
Mosman to lead NanoKar’s next phase of translational validation, partner readiness, and strategic collaboration for its ITAM optimization platform
Lumea Named Best New Biopsy Technology Solution in 2026 MedTech Breakthrough Awards
Recognition places Lumea among elite global winners including Medtronic and Thermo Fisher Scientific in one of digital health’s most competitive annual programs
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
Recent pathogens illustrate need for improved situational awareness capabilities, such as those provided by the Co-Dx PCR point-of-care platform
BlueWind Medical Secures $47.8 Million Financing to Accelerate Commercialization of Revi® System
Funds will fuel sales team expansion and broader market access, advancing the company’s leadership in Implantable Tibial Neuromodulation (ITNM) for the treatment of urgency urinary incontinence (UUI)
PhotoPharmics Announces Last Patient Last Visit in Pivotal, Phase 3, Light for PD Clinical Trial; Company to Present Topline Data at World Parkinson Congress
351-patient trial completion marks a key milestone for the Celeste® program; topline data to be presented May 26 in Phoenix
AFTER SUCCESSFUL FDA MEETING, CLENE FILING ACCELERATED APPROVAL NDA FOR ALS
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society’s 2026 Annual Meeting
VOXZOGO is the only approved treatment for children with achondroplasia starting at birth, with over 10 years of clinical research demonstrating the long-term benefit on complications associated with achondroplasia
Two ARUP Medical Directors Receive Career Achievement Awards
Two ARUP Medical Directors Receive Career Achievement Awards
Canary Speech Introduces Free Voice-Based Check-In for Consumers to Help Identify Early Signs of Mental Health Decline
As gaps in early detection persist, a 45-second voice analysis offers a new way to identify signals of stress, anxiety, and depression during Mental Health Awareness Month
What to Know About the Reauthorized SBIR/STTR Grant Programs
What to Know About the Reauthorized SBIR/STTR Grant Programs
